Alpha Tau Medical Confirms No Direct Exposure to Silicon
JERUSALEM, March 12, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ('Alpha Tau', or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today issued the following statement on Silicon Valley Bank (SVB) in response to questions from investors and analysts.
We maintain no accounts or other financial relationships with SVB, and we do not currently expect its closure to have any impact on our operations.
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
About Alpha Tau Medical, Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Forward-Looking Statements
This press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including 'anticipate,' 'being,' 'will,' 'plan,' 'may,' 'continue,' and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Alpha Tau's current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau's ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau's limited operating history; (iii) Alpha Tau's incurrence of significant losses to date; (iv) Alpha Tau's need for additional funding and ability to raise capital when needed; (v) Alpha Tau's limited experience in medical device discovery and development; (vi) Alpha Tau's dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau's clinical studies to predict final study results; (viii) failure of Alpha Tau's early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau's ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau's Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau's exposure to patent infringement lawsuits; (xii) Alpha Tau's ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq's listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption 'Risk Factors' in Alpha Tau's annual report filed on form 20-F with the SEC on March 9, 2023, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau's views as of any date subsequent to the date of this press release.
Investor Relations Contact:
IR@alphatau.com

TIN LIÊN QUAN
Mablink Bioscience to Present Promising Preclinical Data
Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023 In vivo antitumor efficacy with...
CoinShares confirms no impact to operations from recent
13th March 2023 | SAINT HELIER, Jersey | CoinShares International Limited (“CoinShares” or “the Company”) (Nasdaq Stockholm: CS; US OTCQX: CNSRF), the...
Agenus Schedules Conference Call to Discuss the Company’s
Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET...
Small Pharma to Host Virtual Roundtable Event with Key
LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company...
NeuroMetrix, Inc. Announces Date for Fourth Quarter and
WOBURN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 fourth quarter and year...
THỦ THUẬT HAY
[Video] Hướng dẫn tải về iOS 10 Beta trên iPhone
Vào đêm qua tại sự kiện WWDC 2016, Apple đã chính thức giới thiệu iOS 10 với nhiều tính năng mới như: Siri thông minh hơn, màn hình khóa kiểu mới, iMessage nhiều tính năng hơn, bản đồ giao diện mới, Home kit, Apple
Hướng dẫn tạo ra các bức ảnh chồng hình vô cùng nhanh trên smartphone
Ở bài viết này mình sẽ sử dụng đến ứng dụng Afterlight của nhà phát triển Afterlight Collective, Inc. Ứng dụng đang được cung cấp 2 hệ điều hành Android và iOS. Ngoài Afterlight, bạn cần chuẩn bị 2 tấm hình để thực
Hướng dẫn chặn ứng dụng Android tự động cập nhật
Tốt nhất, bạn hãy tắt tính năng tự động cập nhật ứng dụng trên Google Play đi. Khi nào cảm thấy cần thiết hoặc rảnh rỗi thì cập nhật những ứng dụng mình thích, còn những ứng dụng ít khi sử dụng thì tạm để cập nhật sau
Nhanh tay nhận ngay bản quyền trọn đời DxO Optics Pro 9 Elite trị giá 199 USD
Nhà phát triển DxO Labs đang có chương trình khuyến mãi lớn, miễn phí bản quyền trọn đời DxO Optics Pro 9 Elite Edition trị giá 199 USD - Phần mềm xử lý, chỉnh sửa và tối ưu hóa ảnh chuyên nghiệp, phù hợp cho các nhiếp
Hướng dẫn cắm hoa 8/3 đẹp lung linh trên điện thoại
Sẽ rất đáng yêu nếu chúng ta biết trang trí những nhành hoa, đóa hoa sáng màu lấp lánh cho điện thoại của phái nữ nhân ngày 8/3.
ĐÁNH GIÁ NHANH
So sánh nhanh Xperia XA2 và XA2 Ultra với các đối thủ tầm trung khác
Như vậy là sau một thời gian xuất hiện dưới dạng tin đồn thì mới đây, bộ đôi smartphone tầm trung Xperia XA2 và XA2 Ultra cũng được Sony chính thức trình làng tại sự kiện CES 2018 đang diễn ra tại Mỹ.
Samsung Galaxy Buds2 có đáng mua hay không?
Samsung Galaxy Buds2 là chiếc tai nghe không dây vô cùng hấp dẫn với thiết kế tối ưu cùng nhiều tính năng hấp dẫn. Vậy Samsung Galaxy Buds2 có đáng mua hay không? Mời bạn cùng tham khảo ngay bài viết này của chúng tôi